At a glance
- Originator Lundbeck A/S
- Class Anxiolytics; Piperazines; Small molecules; Spiro compounds
- Mechanism of Action Opioid receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anxiety disorders
Most Recent Events
- 23 May 1995 Discontinued-Preclinical for Anxiety disorders in Denmark (Unknown route)